Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

BACKGROUND. This SafeHer subgroup analysis assessed the safety of fixed‐dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2‐positive early breast cancer (EBC) by body weight. PATIENTS AND METHODS. Patients with HER2‐positive EBC not previously treated with anti‐HER2 therapy received...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Jung, Kyung Hae, Ataseven, Beyhan, Verrill, Mark, Pivot, Xavier, De Laurentiis, Michelino, Al‐Sakaff, Nedal, Lauer, Sabine, Shing, Mona, Gligorov, Joseph, Azim, Hamdy A.
Формат: Artigo
Язык:Inglês
Опубликовано: AlphaMed Press 2018
Предметы:
Breast Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6263135/
https://ncbi.nlm.nih.gov/pubmed/30018134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0065
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы